Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mike David

Physician Assistant Bronx, NY Physician Assistant

NPI 1013469295 CMS profile 11109297

1455 West Ave, Bronx, NY 10462

Open in the dashboard

General payments

$5,402

256 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mike David of Bronx, NY is reported in the CMS Open Payments database as having received $5,402 across 256 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,912 92
2024 General $1,121 43
2023 General $995 43
2022 General $707 37
2021 General $667 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mike David
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Mike David were reported at $1,912. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Mike David Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $667 $132 $37–$438 $132
2022 $707 $155 $48–$522 $149
2023 $995 $167 $52–$557 $160
2024 $1,121 $178 $55–$600 $164
2025 $1,912 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,412 71 payments
  2. Pfizer Inc. $691 26 payments
  3. Arcutis Biotherapeutics, Inc. $519 31 payments
  4. Janssen Biotech, Inc. $448 19 payments
  5. Genzyme Corporation $427 14 payments
  6. Amgen Inc. $338 16 payments
  7. LEO Pharma Inc. $317 26 payments
  8. Incyte Corporation $269 15 payments
  9. E.R. Squibb & Sons, L.L.C. $258 6 payments
  10. Dermavant Sciences, Inc. $134 6 payments
  11. Other $588 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,271 253 payments
  2. Education $131 3 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI Immunology $803 41 payments
  2. DUPIXENT $655 21 payments
  3. CIBINQO $607 23 payments
  4. TREMFYA $448 19 payments
  5. Zoryve $400 25 payments
  6. EUCRISA $352 16 payments
  7. Otezla $338 16 payments
  8. SKYRIZI Immunology $311 14 payments
  9. OPZELURA $269 15 payments
  10. SOTYKTU $258 6 payments
  11. Other $1,896 101 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

2,811

Median for Physician Assistant: 241

Drug cost

$149,161

Median for Physician Assistant: $4,110

Branded share of claims

3.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opzelura Ruxolitinib Phosphate Brand 20 $39,864
Clobetasol Propionate Generic 258 $16,407
Calcipotriene Generic 65 $14,842
Zoryve Roflumilast Brand 14 $13,871
Halobetasol Propionate Generic 216 $12,451
Clindamycin Phosphate Generic 192 $10,922
Ammonium Lactate Generic 373 $9,099
Metronidazole Generic 146 $6,208
Tacrolimus Generic 23 $4,037
Ketoconazole Generic 319 $3,689

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$22,663

Of which drugs: $61

Medicare patients

80

Average age 68

Services billed

464

48 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 48%
Arthritis 44%
Chronic kidney disease 21%
Ischemic heart disease 20%
Depression 18%
Heart failure 16%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 81 $61

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CIBINQO
  • PFIZER INC. $196
$196 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $192
$192 14 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $173
$173 — —
DUPIXENT
  • GENZYME CORPORATION $87
  • Regeneron Healthcare Solutions, Inc. $48
$135 — —
SKYRIZI
  • AbbVie, Inc. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record